<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254917</url>
  </required_header>
  <id_info>
    <org_study_id>E2I29</org_study_id>
    <nct_id>NCT00254917</nct_id>
  </id_info>
  <brief_title>Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The present clinical study will assess the immunogenicity and reactogenicity of the&#xD;
      subsequent administration of Aventis Pasteur's DTacP-IPV//PRP~T combined vaccine&#xD;
      (PENTAVAC™/PENTAXIM), as a three-dose primary vaccination in 6, 10 and 14 weeks of age&#xD;
      schedule followed by a booster vaccination during the second year of life with the aim to&#xD;
      cover the WHO EPI primary vaccination schedule at this age for diphtheria, tetanus,&#xD;
      pertussis, poliomyelitis and Hib vaccines.&#xD;
&#xD;
      WHO EPI vaccination schedules for hepatitis B (either 0, 6 and 14 weeks or 6, 10 and 14 weeks&#xD;
      of age) will be also assessed in infants born to HBsAg seronegative mothers.&#xD;
&#xD;
      To assess the safety of Pentaxim.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, randomized, multicentric, controlled trial. Infants will be randomly allocated in one&#xD;
      of the two study groups as follows:&#xD;
&#xD;
      Group A: 212 subjects will receive the PENTAXIM™ vaccine at 6, 10 and 14 weeks of age, and&#xD;
      the recombinant 10 µg hepatitis B vaccine at 0, 6 and 14 weeks of age.&#xD;
&#xD;
      Group B: 212 subjects will receive the PENTAXIM™ and the recombinant 10 µg hepatitis B&#xD;
      vaccines at 6, 10 and 14 weeks of age.&#xD;
&#xD;
      All infants included in the study will receive a booster dose of PENTAXIM™ vaccine at 18-19&#xD;
      months of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the safety of PENTAXIM™ Vaccine.</measure>
    <time_frame>20 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">387</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Polio</condition>
  <condition>Pertussis</condition>
  <condition>Haemophilus Influenzae Type B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>2</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed by one or both parent(s) and/or by a legally accepted&#xD;
             representative prior to the first study intervention&#xD;
&#xD;
          -  Healthy male or female newborn&#xD;
&#xD;
          -  Age ranging from birth to 48 hours of life (included)&#xD;
&#xD;
          -  Birth weight &gt;2.5 kg and gestational age &gt;37 weeks&#xD;
&#xD;
          -  Born to HBs antigen-negative mother&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known previous therapy of the mother with cadaveric pituitary derived human growth&#xD;
             hormone&#xD;
&#xD;
          -  Infant presently enrolled or scheduled to be enrolled in another clinical trial&#xD;
&#xD;
          -  Infant with moderate or severe illness, mainly infectious diseases&#xD;
&#xD;
          -  Infant with fever (rectal temperature &gt; 38°C or axillary temperature &gt; 37.5°C)&#xD;
&#xD;
          -  Infant with severe congenital defects or abnormalities&#xD;
&#xD;
          -  Uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.&#xD;
&#xD;
          -  Known immunological deficiency (including a known HIV seropositive mother)&#xD;
&#xD;
          -  Administration of vaccine since birth (other than BCG)&#xD;
&#xD;
          -  Previous or planned administration of immunosuppressive therapy, immunoglobulins and&#xD;
             /or any blood-derived products (inhaled and topical corticoids are allowed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>19 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>November 15, 2005</study_first_submitted>
  <study_first_submitted_qc>November 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2005</study_first_posted>
  <last_update_submitted>April 13, 2012</last_update_submitted>
  <last_update_submitted_qc>April 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pentaxim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

